RPCA
AERI

Running Point Capital Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Running Point Capital Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,741
Closed -$81K – 239
2022
Q2 		$81K Sell
10,741
-106
-1% -$747 0.05% 144
2022
Q1 		$99K Buy
+10,847
New +$83.6K 0.06% 138

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Running Point Capital Advisors's AERI Position: Q3 2022 in Review

Running Point Capital Advisors sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 10,741 shares — an estimated $81K sold.

Running Point Capital Advisors first reported a position in AERI in Q1 2022 and held it in 2 quarters. The position peaked at $99K in Q1 2022. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Running Point Capital Advisors reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,741 Aerie Pharmaceuticals shares in Q3 2022, an estimated $81K.
  • Running Point Capital Advisors first reported a position in Aerie Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Running Point Capital Advisors's Aerie Pharmaceuticals position peaked at $99K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Running Point Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.